Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

Part of paid clinical trials in Winston-Salem, North Carolina.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT00690846
Phase
PHASE2
Status
Withdrawn

Conditions

  • Pyoderma Gangrenosum

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • adalimumab — DRUG
    40 mg weekly adalimumab injection.

Study Details

The purpose of this research study is to see if Humira (adalimumab) is effective and safe in the treatment of pyoderma gangrenosum.

Key Dates

Start date
Jul 31, 2007
Status verified
Jul 2018
Primary completion
Jul 31, 2007
Completion
Jul 31, 2007

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    40 mg weekly subcutaneous injection of adalimumab

Primary Outcome Measure

Mean change in the number of ulcers. [ Time Frame: 24 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Wake Forest University Health Sciences DermatologyWinston-SalemNorth Carolina27157-

Find similar trials in Winston-Salem, NC

By research site
Wake Forest University Health Sciences Dermatology· Winston-Salem, NC

Related Studies